论文信息 - First-in-human, multicenter, dose-escalation, phase I study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced nonhematologic malignancies and melanoma. - 字舞流文

First-in-human, multicenter, dose-escalation, phase I study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced nonhematologic malignancies and melanoma.

J. Sosman | A. Ribas | P. LoRusso | A. Adjei | G. Dy | E. Izmailova | B. Chmielowski | S. Faucette | V. Bozon | S. Lee | A. Bowditch | S. A. Michael | R. Walker